SLC28A1: A Drug Target and Biomarker for Nuclear Translocation

Target Name: SLC28A1

NCBI ID: G9154

SLC28A1

SLC28A1: A Drug Target and Biomarker for Nuclear Translocation

Sodium-coupled nucleoside transporter (SLC28A1) is a member of the Absolutely Controlled Nuclear Trafficking (ACNT) family, which is a subfamily of the Sodium Chloride Transporter (SLC) family. The SLC family is a large gene family that includes ten known proteins, including SLC28A1, which is expressed in various tissues and organs, including brain, heart, kidney, and testes. SLC28A1 is a 28kDa protein that is predominantly localized to the nuclei of various cell types.

SLC28A1 functions as a nucleoside transporter, primarily transporting nucleosides out of the nucleus and into the cytoplasm. It is a member of the Translocation of Nucleosides (TON) system, which is a mechanism by which nucleosides are transported across the nuclear membrane and into the cytoplasm. The TON system is driven by the energy provided by the cytoplasmic ATP, which is generated by the GTPase-activated protein (GAP) activity of the nucleoside transport protein.

SLC28A1 has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, psychiatric disorders, and reproductive diseases. For example, SLC28A1 has been shown to be involved in the pathogenesis of Alzheimer's disease. Studies have shown that SLC28A1 is overexpressed in the brains of individuals with Alzheimer's disease, and that inhibition of SLC28A1 has been shown to protect against neurodegeneration in these individuals.

In addition to its potential clinical applications, SLC28A1 has also been studied for its potential as a biomarker for various diseases. For example, SLC28A1 has been used as a biomarker for neurodegenerative disorders, including Alzheimer's disease. Studies have shown that SLC28A1 levels are significantly increased in the brains of individuals with neurodegenerative disorders, and that inhibition of SLC28A1 has been shown to improve cognitive function in these individuals.

SLC28A1 has also been used as a biomarker for psychiatric disorders, including depression and anxiety. Studies have shown that SLC28A1 levels are increased in the brains of individuals with major depressive disorder (MDD) and anxiety disorders, and that inhibition of SLC28A1 has been shown to improve mood and cognitive function in these individuals.

In addition to its potential clinical and biomarker applications, SLC28A1 is also of interest as a potential drug target. Studies have shown that SLC28A1 is involved in the regulation of cellular processes that are critical for the survival and proliferation of cancer cells, including cell division, apoptosis, and angiogenesis. Therefore, inhibition of SLC28A1 has been shown to be a potential strategy for cancer treatment.

In conclusion, SLC28A1 is a nuclear transporter that is involved in the regulation of nucleoside transport and the TON system. It has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, psychiatric disorders, and reproductive diseases. Further research is needed to fully understand the role of SLC28A1 in these diseases and to develop effective therapies that target this protein.

Protein Name: Solute Carrier Family 28 Member 1

Functions: Sodium-dependent and pyrimidine-selective transporter (PubMed:9124315, PubMed:21998139, PubMed:10455109, PubMed:30658162). Exhibits the transport characteristics of the nucleoside transport system cit or N2 subtype (N2/cit) (selective for pyrimidine nucleosides and adenosine) (PubMed:21998139). Transports uridine, cytidine, thymidine, and nucleoside-derived drugs (PubMed:21795683, PubMed:21998139). Transports the antiviral pyrimidine nucleoside analogs 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (ddC) (PubMed:9124315). It may be involved in the intestinal absorption and renal handling of pyrimidine nucleoside analogs used to treat acquired immunodeficiency syndrome (AIDS) (PubMed:9124315). It has the following selective inhibition: adenosine, thymidine, cytidine, uridine >> guanosine, inosine (PubMed:9124315)

The "SLC28A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC28A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets